Ocugen raises $40M to fund late-stage gene therapy push

What's the deal? Ocugen (NASDAQ: OCGN) has raised $40 million in a registered direct offering, selling 20,000,000 shares of common stock at $2.00 each. A single institutional healthcare-focused investor took the entire round.

The terms: The shares were priced at-the-market, and the offering is expected to yield roughly $40 million in gross proceeds before placement agent fees and other expenses. Closing is expected on or about February 12, 2026.

What's the endgame? Ocugen is advancing three late-stage gene therapy programs targeting blindness diseases: OCU400 for retinitis pigmentosa, OCU410ST for Stargardt disease, and OCU410 for geographic atrophy. It plans to use net proceeds for working capital and general corporate purposes, including funding ongoing clinical trials.

Why now? Management is pursuing potential biologics license application (BLA) submissions for all three programs by 2028. That is a capital-intensive effort, and the financing strengthens the balance sheet ahead of it.

The signal: For a clinical-stage biotech, tapping a single institutional backer signals concentrated conviction in the pipeline — and a runway to keep three programs moving toward regulatory filings.

Read more: minichart.com.sg

Image credit: Generated with Gemini